Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Repaying 31.7% of the Sovereign debt in 12 months is rather impossible
Not repaying, renewing. T-Bills get rolled over, not repaid.
Do they need an AG to compete on price?
That is of course the valid point, but it leaves one with unsatisfactory situations, like the SEC under Cox.
That post must have been pulled, and rightfully so judging from the garbage you quoted. I unreservedly withdraw my chidings, with apologies.
Unless it was in a deleted post (there appears to have been one, perhaps from jmkobers) I haven't seen any name calling or recrimination from the gentleman.
This board seems to be inordinately sensitive to perceived slights.
(I know nothing about jmkobers. He may well be a paid basher, but whether he is or not is immaterial to me. And MNTA has been doing fine without any bashing lately.)
Good point. I tried to suggest a little while ago that there are dangers in a board koolaided by such a strong positive consensus and was told in no uncertain terms by three respected contributors that some one as naive and stupid as me should not be investing in biotech. Forget what the stock was at then, but it was well above 15.50.
Am looking to go back into MNTA now. It may be time.
Mackay lives!
I'm beginning to think Charles Mackay has been resurrected to pen another chapter.
Thank you the advice on my investment posture. All advice gratefully accepted, gratuitous or not. Even when not based on any knowledge of my portfolio.
It's clear that the broad consensus of this board is that SNY has no chance of prevailing in its law suit, and that the chance of TEVA getting an early approval is almost equally low.
Then why is the stock trading like one or other of these concerns is valid?
I've been in situations before where I've substituted my certainty for the doubts of the market. In every case that I can remember, I've lost money.
I would have thought that the potential scalability of the MNTA platform would be one of the company's major attractions
Moves up?
EDIT - Okay, I see that was hours ago.
In other words, you believe there might not be another leg down if a TEVA generic is approved? Today's action prices that in?
(Debating with myself whether to go in towards the close.)
How in heck did you parse the question in such a way as to tease meaning out of that jumble of words?
I think I understood Wheeler to say yes, we can do things we doubt anybody else can.
Acronyms -
That's what I do. Google just DAA and you get garbage. Try DAA HCV and bingo!
or to sell out.
The GENZ 3 minute chart over the last hour is a remarkable sight. There must have been news, manipulated or otherwise, but I have no idea what it was.
They are "HTB" (hard to borrow) at Schwab. That usually means don't ask, at least for my level of customer.
Just a couple of managers who started their DD when they got to the office this morning instead of giving up their golf to work over the weekend.
That's what worries me. A bit too much giddiness in some here.
I should check the Marina to see if my Feadship has been delivered yet.
The Yahoo board is funny in an opposite way, including the jerk (is it always the same guy?) who thinks he's persuading people by yelling TIMBER followed by about 50 R's.
I hope you didn't think I thought there was such a threat. I was flailing around trying to figure out the reason for what I thought was a tepid market response. And since it has been noted that the analysts at the CC were clueless....
I can't find it easily because I'm a freeloader, but I believe Dew did address (and as I remember, dismiss) the possibility of legal challenge. I reproduced the WSJ quote because I was puzzled by the reaction - tepid, given the importance of the approval for MNTA in this product and others like Copaxone - and wondered whether some might be waiting on clarification of the legal issue.
More likely, perhaps, given the lack of preparation by the analysts at the CC, may be that they felt the need to go back and research the financial implications of the approval for MNTA. Maybe Monday will tell us whether their weekend was spent fruitfully.
I know the possibility of legal complications has been discussed here, but this snippet from the WSJ sums it up starkly. Enthusiasm may be muted until this is cleared away.
The FDA's decision may provoke legal action. Amphastar says the FDA showed favoritism in picking Momenta, which helped the agency investigate deaths caused by imports of contaminated Chinese heparin in 2008. Amphastar's lawyers said Friday the company would do everything possible to change what it called a "wrong" decision.
Momenta Chief Executive Craig Wheeler cautioned analysts Friday that Sanofi also may bring legal action. Sanofi, which has said Lovenox is too complex to be copied safely, declined to comment on any possible litigation. Mr. Wheeler said Momenta and Sandoz had been working toward Friday's approval for eight years. "We have been looking forward to this particular call for a very long time," he said. "We have said in that past that we will be ready to launch upon approval, and we are."
Actually NVS was down quite heavily (to 48.60) and rallied fairly strongly on the news. I know because I was about to put in a buy when it zipped away.
Won't happen unless the 3.8 mil shorts head for the door at once.
Even if one believes a stock like MNTA is a POS, it's inconceivable to me that one would take a short position in such a potentially explosive situation.
Brokerages such as E*Trade and MB Trading don't have programs to let customers lend securities
MB Trading clears through Penson so the latter's policies would govern. Penson is restrictive, and often lists a security as unborrowable when it's available for shorting elsewhere
There must be a very valid reason, but why not return whole blood to the subject? Forget the apherisis.
Looking at NVS' market action today, some are now asking that Diovan question.
Don't you mean secular bear markets last a long time?
Who is Patrick Cox and what are his affiliations?
Bear Stearns?
My wife and I bought into 23andme and got reports that were mildly interesting. But when we received e-mails about updates (like the relative finder), we could not access them because we share the same e-mail address - that discombulates the system, apparently. Their "fixes", applied to the letter, never worked. So we gave up. If they can't figure out a double e-mail glitch, they probably can't figure out a lot of other things connected with their service.
BRIC I got. MT = Malaysia Thailand?
I don't own CYCC at this time, but it's one of those "you will be amazed at the wonderful drugs for a raft of significant indications we have in our pipeline" - but everything remains in the future, though sapacitabine in MDS will be presented at ASCO, and that should be a moment of truth.
Because the indications it's working on are so potentially lucrative I will keep it on my screen and drop in on the Yahoo board from time to time, but so far it's more promise than delivery.
Agreed. Essentially it was no news, and a case where no news is neither good nor bad. Though you wouldn't know that from the market reaction.
As far as Rida failing, the Independent Data Monitoring Committee recommended that the trial "continue to its final analysis, without modification."
Isn't that recommendation neutral on the question whether Rida will eventually fail or not?
Who on earth are the buyers?
Is there much in there that hasn't been SOP in the industry for eons?
There was discussion initiated by Biotech Jim on the SI Valuation thread on 2/10/10. Nothing that might be called significant DD, though.
I don't see anything approaching 7 on the Schwab one minute chart.
Anybody have a T&S?